EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Neuroblastoma (NB) is the most common extracranial pediatric solid tumor with an undifferentiated status and generally poor prognosis, but the basis for these characteristics remains unknown. In this study, we show that upregulation of the Polycomb protein histone methyltransferase EZH2, which limits differentiation in many tissues, is critical to maintain the undifferentiated state and poor prognostic status of NB by epigenetic repression of multiple tumor suppressor genes. We identified this role for EZH2 by examining the regulation of CASZ1, a recently identified NB tumor suppressor gene whose ectopic restoration inhibits NB cell growth and induces differentiation. Reducing EZH2 expression by RNA interference-mediated knockdown or pharmacologic inhibiton with 3-deazaneplanocin A increased CASZ1 expression, inhibited NB cell growth, and induced neurite extension. Similarly, EZH2(-/-) mouse embryonic fibroblasts (MEF) displayed 3-fold higher levels of CASZ1 mRNA compared with EZH2(+/+) MEFs. In cells with increased expression of CASZ1, treatment with histone deacetylase (HDAC) inhibitor decreased expression of EZH2 and the Polycomb Repressor complex component SUZ12. Under steady-state conditions, H3K27me3 and PRC2 components bound to the CASZ1 gene were enriched, but this enrichment was decreased after HDAC inhibitor treatment. We determined that the tumor suppressors CLU, NGFR, and RUNX3 were also directly repressed by EZH2 like CASZ1 in NB cells. Together, our findings establish that aberrant upregulation of EZH2 in NB cells silences several tumor suppressors, which contribute to the genesis and maintenance of the undifferentiated phenotype of NB tumors.

[1]  J. Khan,et al.  CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression , 2011, Cell Death and Differentiation.

[2]  Lu Gan,et al.  Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2 , 2010, Nature Cell Biology.

[3]  Guy Sauvageau,et al.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. , 2010, Cell stem cell.

[4]  L. Boyer,et al.  Polycomb group proteins set the stage for early lineage commitment. , 2010, Cell stem cell.

[5]  Ji-Eun Lee,et al.  Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis , 2010, Proceedings of the National Academy of Sciences.

[6]  Nicolò Riggi,et al.  EZH2 is essential for glioblastoma cancer stem cell maintenance. , 2009, Cancer research.

[7]  Kristian Helin,et al.  Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.

[8]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[9]  F. Westermann,et al.  Molecular characterization and classification of neuroblastoma. , 2009, Future oncology.

[10]  N. Sebire,et al.  Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. , 2009, Journal of the National Cancer Institute.

[11]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[12]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[13]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[14]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[15]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[16]  Stefano Bonassi,et al.  Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome‐wide expression analysis and game theory , 2008, Cancer.

[17]  J Khan,et al.  The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.

[18]  J. Maris,et al.  CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas , 2008, Journal of the National Cancer Institute.

[19]  Yuri Kotliarov,et al.  Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.

[20]  T. Veenstra,et al.  Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases , 2007, Proceedings of the National Academy of Sciences.

[21]  D. Ghosh,et al.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.

[22]  H. Carén,et al.  Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours , 2007, British Journal of Cancer.

[23]  J. Mchugh,et al.  Expression of polycomb group protein EZH2 in nevi and melanoma , 2007, Journal of cutaneous pathology.

[24]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[25]  Kristian Helin,et al.  The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.

[26]  H. Vogel,et al.  CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.

[27]  Tommy Martinsson,et al.  Neuroblastoma tumors with favorable and unfavorable outcomes: Significant differences in mRNA expression of genes mapped at 1p36.2 , 2007, Genes, chromosomes & cancer.

[28]  C. Thiele,et al.  Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation. , 2006, Biochemical and biophysical research communications.

[29]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[30]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Houghton,et al.  Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo , 2006, Clinical Cancer Research.

[32]  E. Connolly,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.

[33]  J. Khan,et al.  Altered expression of cell cycle genes distinguishes aggressive neuroblastoma , 2005, Oncogene.

[34]  Takeshi Inoue,et al.  Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. , 2005, Biochemical pharmacology.

[35]  L. Hesson,et al.  A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation , 2005, Molecular Cancer.

[36]  G. Melino,et al.  Mechanism of Induction of Apoptosis by p73 and Its Relevance to Neuroblastoma Biology , 2004, Annals of the New York Academy of Sciences.

[37]  Qing-Rong Chen,et al.  Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma , 2004, Cancer Research.

[38]  G. Chatta.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer , 2003 .

[39]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[40]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[42]  Rogier Versteeg,et al.  Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma , 2003, Genes, chromosomes & cancer.

[43]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[44]  R. Stallings,et al.  Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? , 2003, Cancer genetics and cytogenetics.

[45]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[46]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[47]  S. Itohara,et al.  Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.

[48]  C. Eng,et al.  RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours , 2001, Oncogene.

[49]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[50]  C. Rieder,et al.  Greatwall kinase , 2004, The Journal of cell biology.

[51]  W. Odenwald,et al.  castor encodes a novel zinc finger protein required for the development of a subset of CNS neurons in drosophila , 1992, Neuron.